U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06928259) titled 'Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV' on April 07.
Brief Summary: Background: Currently used direct-acting antivirals (DAA) share pharmacokinetic pathways with many comedications commonly used in patients with chronic hepatitis C virus (HCV) infection, therefore drug-drug interactions (DDI) might exist. Although extensive (DDI) verification is recommended by most clinical practice guidelines, real-world studies have shown that approximately one-tenth of patients on DAA therapy also take concomitant medication with the potential for significant interactions. Despite the risk of significant DDI when p...